Results 31 to 40 of about 23,326 (221)

Reduction in hospitalisations with dupilumab in Japanese adults with atopic dermatitis in a real‐world setting

JEADV Clinical Practice, 2023
Background In a recent post hoc analysis of multinational clinical trial data, dupilumab treatment for patients with moderate or severe atopic dermatitis (AD) reduced all‐cause and AD‐related hospitalisations.
Ken Igawa, Hiroyuki Fujita, Yuki Tajima, Robert Lubwama, Moataz Daoud, Zhixiao Wang, Kazuhiko Arima   +6 more
doaj   +1 more source

Atopic eczema [PDF]

, 2016
Atopic eczema is an itchy inflammatory skin disease with a chronic relapsing–remitting course; it has increased in prevalence in recent decades and now affects up to 25% of school-aged children in the developed world and up to 10% of adults.
Deckert, Flohr, Kelleher, Madhok, Nankervis, Rodriguez, Simpson, Williams   +7 more
core   +2 more sources

Real-world treatment patterns in patients with chronic rhinosinusitis with nasal polyps who initiated dupilumab: A US claims analysis

Journal of Allergy and Clinical Immunology: Global
Background: Dupilumab was approved as an add-on maintenance treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps based on the pivotal phase 3 trials.
Jayant M. Pinto, MD, Mirko Fillbrunn, PhD, Bruno Martins, PhD, Min Yang, PhD, Chao Chen, PhD, Scott Nash, MD, Mark Corbett, MD, Aakash Gandhi, PhD, Zhixiao Wang, PhD   +8 more
doaj   +1 more source

Psoriasis appearing after dupilumab therapy in atopic dermatitis: A case report

SAGE Open Medical Case Reports, 2020
A 36-year-old Caucasian female with a long history of atopic dermatitis presented with multiple flares eventually leading to dupilumab therapy. Five months into the dupilumab therapy, she presented with well-demarcated erythematous plaques with silvery ...
Ho Seung Kim, Jensen Yeung
doaj   +1 more source

We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma [PDF]

, 2018
Interleukin.5 (IL.5) is the main eosinophilic cytokine that promotes the differentiation, survival, and activation of eosinophils, which are the key inflammatory cells in severe eosinophilic asthma .Thus, it is no surprise that ...
4,, BEGHE', Bianca, Fabbri, Lm3, Papi, A1   +3 more
core   +1 more source

Tumors in the setting of dupilumab use: A review of the literature

World Allergy Organization Journal
Dupilumab is the first monoclonal antibody approved for treating moderate-to-severe atopic dermatitis (AD) and has significantly improved the quality of life of AD patients.
Shumeng Guo, Liangchun Wang, MD, PhD, Dingfang Bu, MD, PhD, Fengjie Liu, MD, PhD   +3 more
doaj   +1 more source

Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma

ERJ Open Research, 2023
Background The phase 3 QUEST (NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab 200/300 mg versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab 300 mg up to an additional 96 weeks (TRAVERSE) in patients ≥12 
Jonathan Corren, Constance H. Katelaris, Mario Castro, Jorge F. Maspero, Marc Humbert, David M.G. Halpin, Arman Altincatal, Nami Pandit-Abid, Xavier Soler, Amr Radwan, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe   +12 more
doaj   +1 more source

Severe Atopic Dermatitis In Spain: A Real-Life Observational Study [PDF]

, 2019
Objective: To determine the epidemiology and characterize the treatment prescribed for severe atopic dermatitis (AD) in children/adults in usual clinical practice.
Armario Hita, José Carlos, Navarro-Artieda, Ruth, Sicras-Mainar, Antoni   +2 more
core   +2 more sources

Molecular mechanisms in atopic eczema:insight gained from genetic studies [PDF]

, 2017
Atopic eczema (synonymous with atopic dermatitis and eczema) is a common heterogeneous phenotype with a wide spectrum of severity from mild transient disease to a severe chronic disorder with atopic and non-atopic co-morbidities.
Adoue, Barrett, Baurecht, Beck, Bieber, Boguniewicz, Broussard, Brown, Brown, Brown, Brown, Brown, Brown, Brown, Caubet, Cole, Deckert, Esaki, Esparza-Gordillo, Eyerich, Gao, Ghosh, He, He, Henderson, Horimukai, Hotze, Howell, Hubiche, Irvine, Johansson, Kelleher, Kelleher, Kim, Liu, Margolis, Margolis, McAleer, Noda, Odhiambo, Paller, Paller, Palmer, Paternoster, Rodriguez, Samuelov, Sandilands, Schmitt, Schmitt, Silverberg, Simpson, Smith, Strom, Suarez-Farinas, Takai, Tang, Taylan, Thaci, Tsianakas, Walley, Weidinger, Weidinger, Williams, Williams, Zhang   +64 more
core   +2 more sources

Feasibility of continued treatment with dupilumab in patients with type 2 inflammatory disease who developed eosinophilic pneumonia: 3 case reports

Respirology Case Reports
Several reports have described dupilumab‐induced eosinophilic pneumonia (EP) after treatment with dupilumab in patients with type 2 inflammatory disease. Other reports have suggested the efficacy of dupilumab for chronic EP (CEP).
Masamitsu Hamakawa, Ayaka Tanaka, Fumiaki Tokioka, Tadashi Ishida   +3 more
doaj   +1 more source